Browse
Recent Presentations
Recent Stories
Content Topics
Updated Contents
Featured Contents
PowerPoint Templates
Create
Presentation
Article
Survey
Quiz
Lead-form
E-Book
Presentation Creator
Create stunning presentation online in just 3 steps.
Pro
Get powerful tools for managing your contents.
Login
Upload
Content Directory
Content Directory
t
t-rv-nyi-szab-ly -> table-of-content
table-1-list-of- -> table-1-transmis
Table 1: Transmissible spongiform encephalopathies
Table 1 List of the patient's medications at the time of presentation
Table 1 LUTO subtypes and associated anomalies with total prevalence
Table 1 Major autophagy proteins
Table 1 MAPI assessment of donor kidney biopsy samples
Table 1 Mean annual precipitation (mm).
Table 1 Microparticles as biomarkers of rheumatic diseases: clinical studies and findings
TABLE 1 : MIEUX-ÊTRE ET DÉVELOPPEMENT DES COMMUNAUTÉS
Table 1 Milestones in HCC research reported during the past 30 years*
Table 1 Mitotic index in patient samples
TABLE 1 Modified Wells Criteria Clinical Assessment for pulmonary embolism
Table 1 Molecularly targeted drugs that are being used in phase I/II trials to treat brain tumors
Table 1 – msInspect usage
Table 1. NAME FIELD OBSERVATIONS
Table 1. Nontraditional PharmD program comparison 2
Table 1 Occupational injury with more than 30 days disability and/or permanent impairment,
Table 1. Occurrence of N-X-S/T motives in tryptic peptides 1
TABLE 1 Oligonucleotide primers and probes used in dot blots and DGGE analysis
Table 1 Ongoing clinical trials of passive Aβ immunotherapies
Table 1 Other DAMPs, their specific receptors, and possible immune-potentiating effects
Table 1 Outcomes from ACAS and ACST
Table 1 Overview of HSAN subtypes
Table 1. Parameter estimates of fit in Fig. 1. Units: rate constants=1/day, cells numbers=10 4 .
Table 1 . Parameter estimates of the BIS and cAAI model
Table 1 . Parameter estimates of the BIS and cAAI model
Table 1: Parameters of the RT focusing periods
Table 1: Participating States
Table 1 Pathological and clinical features of ALS and FTLD subtypes
Table 1. Patient Characteristics
Table 1 Patient cohort of the cystinuria clinic at Guy’s and St Thomas’ London
Table 1 Patient's initial laboratory values and normal ranges
Table 1 Patient selection guidelines from selected groups for APBI
Table 1 Patients with late relapses described in the CORONA/SATURN and IMDC studies
Table 1. Peak Age Predilection of Bone Lesions
Table 1. Penetrance and Severity of T b 4 knockdown embryo phenotype
Table 1 : Percentage of positive samples found in the different culture media.
Table 1. Percentages of Children who Scored in the Clinical Range on the AYCE and MBQ Subscales
Table 1 Persistent benefits after withdrawal of biologic therapy for pJIA in RCWTs
Table 1 Pharmacokinetic and pharmacodynamic characteristics of oral factor Xa inhibitors
Table 1 Pharmacokinetic properties of intravenous iron formulations
Table 1 Phase III trials with a survival benefit in metastatic CRPC
Table 1 Planned or ongoing clinical trials of radioembolization in patients with mCRC
Table 1 Possible molecular targets and corresponding biologic agents in SLE
Table 1. Potential causes of seizures in pregnancy and postpartum.
TABLE 1
Table 1. - Properties of 2014 Aluminum Alloys.
Table 1. Properties of primitive lymphoid progenitors.
Table 1 Randomized, controlled palliative care interventions in cancer population
Table 1. Recognized families of pathogenesis-related proteins
Table 1. Respondent department demographics
Table 1 Results of radical cystectomy
Table 1 Results of SBRT trials in early stage non-small cell lung cancer
Table 1 Risk factors for development of hyponatremic encephalopathy
Table 1 Risk of progression to HGD/OAC based on presence of hiatal hernia
Table 1 : Sampling Framework
Table 1. Scoring system for tympanic dehiscence & mastoid suture
Table 1 Selected characteristics of the HEMO and MPO study
Table 1 Selected gene mutations that increase the risk of SUDEP
Table 1 Selected large series of LPD and RAPD
Table 1 Selected studies comparing AKI classification schemes
Table 1 Severe Foodborne Illness Annual Burden-of-Illness Estimates
Table 1 Severe Foodborne Illness Caused by Campylobacter spp annual burden-of-illness estimates
Table 1. Shipping costs, Supply, and Demand for Powerco Example
Table 1. Shipping costs, Supply, and Demand for Powerco Example
Table-1: Simulation Parameters
Table 1 Single-agent docetaxel and combined chemotherapy regimens for prostate cancer
Table 1. Social Interdependence Theory (Johnson & Johnson, 2011. p5.)
Table 1 Socio-demographic Characteristics of Immigrant Parents and their Children in Spain, 2010
Table 1 Socio-demographic Characteristics of Immigrant Parents and their Children in Spain, 2010
Table 1 Soil chemical property of each sampling site at sampling time.
Table 1 Soybean sample composition
Table 1: Spark parameters for 8 fibres examined.
Table 1:Start up intervention plan
Table 1. Statistics for short-beaked common dolphin mitochondrial
Table 1 STDs: loci of infection and resultant pathologies
Table 1 Stratification schemes for estimating risk of GIST recurrence after surgery
Table 1 Studies demonstrating the prevalence of TB, EPTB and GUTB
Table 1 Studies evaluating the efficacy of PPIs and H 2 RAs in newborns, infants and children
Table 1 Studies of FFR compared with noninvasive stress testing to assess myocardial ischaemia
Table 1 Success rates for male sling surgery
Table 1 Suggested main diagnostic features of DISH
Table 1 Summary of LTSP in Mg alloys subject to ECAP processing.
Table 1 Summary of reported cases of Down syndrome and in utero onset leukemia
Table 1 Summary of reported therapeutic trials for progressive multifocal leukoencephalopathy 123
Table 1 Summary of selected potential biomarkers in EGPA
Table 1 Summary of studies of primary BAD diagnosed by SeHCAT
Table 1. Syntactic rules and their probabilities.
Table 1 T-cell characteristics in mouse and human arthritis
Table 1: T-test on age uses Satterthwaite approximation for unequal variances.
Table 1 Technical and acquisition parameters for cardiac examinations with MDCT
Table 1 :The Antioxidative capacity of an “Antioxidant” is determined by its:
Table 1 The epidemiology of NAFLD-associated HCC
Table 1 The Evolution of Production and Its Organization
Table 1 The Evolution of Production and Its Organization
Table 1 The Evolution of Production and Its Organization
Table 1 The Evolution of Production and Its Organization
Table 1: The overall dislocation rate, including partial and complete, was found to be 26.3%.
Table 1: Timeline and Data Collected
Table 1 Timing of clinical trials and FDA approval for selected targeted therapies
Table 1 to reactivate HIV-1 from latency
Table 1 to reactivate HIV-1 from latency
Table 1 to reactivate HIV-1 from latency
Browse slideshows:
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z
0
1
2
3
4
5
6
7
8
9